文献速递系统性红斑狼疮

II型抗CD20抗体奥妥珠单抗在狼疮小鼠模型中比利妥昔单抗更有效清除B细胞并治疗疾病

The Type II Anti-CD20 Antibody Obinutuzumab (GA101) Is More Effective Than Rituximab at Depleting B Cells and Treating Disease in a Murine Lupus Model.
PubMed 文献 · Arthritis Rheumatol · 2021-03-24

研究在表达人CD20的MRL/lpr狼疮小鼠中比较II型抗CD20单抗奥妥珠单抗(GA101)与I型利妥昔单抗(RTX)的B细胞清除效果及疾病治疗作用。单剂GA101清除B细胞显著优于RTX(P<0.05);GA101治疗早期疾病可减轻肾小球肾炎(P<0.05)、降低抗RNA自身抗体滴度(P<0.05)并减少活化CD4+ T细胞(P<0.0001),且对晚期疾病有效并延长生存。

要点

  • 单剂GA101在患病MRL/lpr小鼠中清除B细胞显著优于RTX(P<0.05)。
  • GA101治疗早期疾病较RTX更有效减轻肾小球肾炎并降低自身抗体。
  • GA101对晚期疾病有效,持续治疗可延长生存。

核心结论

  • GA101在肾小球肾炎评分等重要参数上比利妥昔单抗更有效,且在晚期疾病模型中延长生存,支持在SLE和狼疮肾炎中开展临床试验。

研究设计与样本

  • 研究使用表达人CD20的狼疮倾向MRL/lpr小鼠(hCD20 MRL/lpr小鼠),分别给予利妥昔单抗或GA101,评估不同条件下的B细胞清除及多个临床终点。

主要发现

  • 单剂GA101在患病MRL/lpr小鼠中清除B细胞显著优于RTX(P<0.05)。
  • RTX通过持续治疗克服了患病MRL/lpr小鼠对B细胞清除的抵抗。
  • GA101治疗早期疾病较RTX更有效:肾小球肾炎减轻(P<0.05)、抗RNA自身抗体滴度降低(P<0.05)、活化CD4+ T细胞减少(P<0.0001)。
  • GA101也能治疗晚期疾病,持续治疗可延长生存。
  • 利用GA101变体阐明了狼疮小鼠体内B细胞清除机制。

临床怎么用

  • 在SLE和狼疮肾炎中,GA101可能较利妥昔单抗更有效清除B细胞并改善肾脏和免疫指标,支持开展临床测试。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Depleting pathogenic B cells could treat systemic lupus erythematosus (SLE). However, depleting B cells in an inflammatory setting such as lupus is difficult. This study was undertaken to investigate whether a type II anti-CD20 monoclonal antibody (mAb) with a different mechanism of action, obinutuzumab (GA101), is more effective than a type I anti-CD20 mAb, rituximab (RTX), in B cell depletion in lupus, and whether efficient B cell depletion results in amelioration of disease. METHODS: We treated lupus-prone MRL/lpr mice expressing human CD20 on B cells (hCD20 MRL/lpr mice) with either RTX or GA101 and measured B cell depletion under various conditions, as well as multiple clinical end points. RESULTS: A single dose of GA101 was markedly more effective than RTX in depleting B cells in diseased MRL/lpr mice (P < 0.05). RTX overcame resistance to B cell depletion in diseased MRL/lpr mice with continuous treatments. GA101 was more effective in treating hCD20 MRL/lpr mice with early disease, as GA101-treated mice had reduced glomerulonephritis (P < 0.05), lower anti-RNA autoantibody titers (P < 0.05), and fewer activated CD4+ T cells (P < 0.0001) compared to RTX-treated mice. GA101 also treated advanced disease, and continual treatment prolonged survival. Using variants of GA101, we also elucidated B cell depletion mechanisms in vivo in mice with lupus. CONCLUSION: Albeit both anti-CD20 antibodies ameliorated early disease, GA101 was more effective than RTX in important parameters, such as glomerulonephritis score. GA101 proved beneficial in an advanced disease model, where it prolonged survival. These data support clinical testing of GA101 in SLE and lupus nephritis.

来源:Arthritis Rheumatol,查看原文。版权归原作者所有。

引用

  1. Marinov AD, Wang H, Bastacky SI, et al. The Type II Anti-CD20 Antibody Obinutuzumab (GA101) Is More Effective Than Rituximab at Depleting B Cells and Treating Disease in a Murine Lupus Model. Arthritis Rheumatol. 2021. PMID: 33277983. doi:10.1002/art.41608

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。